Last updated: August 13, 2026
Sacubitril/valsartan, marketed by Novartis as Entresto, is one of the fastest-growing cardiovascular products in the global pharmaceutical market. Sales increased from about $0.5 billion in 2017 to $6.0 billion in 2023, driven by guideline adoption, expansion into heart failure with preserved ejection fraction, and conversion from ACE inhibitors and angiotensin-receptor blockers. The principal commercial risk is U.S. generic entry after the core patent estate begins to expire in the mid-2020s. Novartis is offsetting that risk through market expansion, formulation differentiation, geographic growth, and lifecycle management.
How large is the sacubitril and valsartan market?
Sacubitril/valsartan has become a leading heart-failure medicine and a major contributor to Novartis sales. Entresto combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II receptor blocker. The product is approved for chronic heart failure across multiple patient populations, including patients with reduced ejection fraction and selected patients with preserved ejection fraction.
What are the main market-growth drivers?
The market has expanded through four channels:
-
Clinical substitution. Entresto replaces ACE inhibitors or ARBs in eligible heart-failure patients, particularly after evidence from the PARADIGM-HF trial showed lower cardiovascular mortality and hospitalization than enalapril in heart failure with reduced ejection fraction (McMurray et al., 2014).
-
Guideline incorporation. U.S. and international guidelines position angiotensin receptor-neprilysin inhibitors as foundational therapy for many patients with heart failure with reduced ejection fraction (Heidenreich et al., 2022).
-
Population expansion. Regulatory and guideline developments have broadened use beyond the initial reduced-ejection-fraction population. The FDA expanded Entresto’s indication in 2021 to include certain adults with heart failure with preserved ejection fraction, although the benefit is more differentiated in patients with mildly reduced or preserved ejection fraction than in reduced ejection fraction (FDA, 2021).
-
Global penetration. Novartis has increased use in Europe, Japan, China, and emerging markets. Reimbursement, diagnosis rates, physician familiarity, and access to specialist care remain uneven, leaving room for volume growth before generic erosion becomes material.
What is the financial trajectory of Entresto?
Entresto has moved from launch-stage growth to blockbuster scale. Novartis reported the following annual net sales:
| Year |
Entresto net sales |
Approximate year-over-year growth |
| 2017 |
$0.5 billion |
198% |
| 2018 |
$1.7 billion |
228% |
| 2019 |
$2.5 billion |
51% |
| 2020 |
$2.5 billion |
Approximately flat |
| 2021 |
$3.5 billion |
42% |
| 2022 |
$4.6 billion |
31% |
| 2023 |
$6.0 billion |
30% |
Source: Novartis annual reports and financial disclosures (Novartis, 2018-2024).
Why did sales accelerate after 2020?
The 2021-2023 acceleration reflected increased diagnosis and treatment of heart failure, wider use in guideline-directed medical therapy, better physician adoption, and continuing growth in international markets. Entresto also benefited from its position as a foundational therapy used alongside beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors.
The product has unusually high strategic value because it is prescribed chronically, has a large target population, and occupies a central position in a treatment pathway with substantial hospitalization costs. Its revenue base is therefore more durable than that of a short-course cardiovascular medicine.
What is the revenue outlook after generic entry?
The U.S. revenue trajectory is likely to divide into three phases:
| Phase |
Commercial condition |
Expected effect |
| Pre-entry growth |
Branded Entresto retains broad coverage and physician preference |
Continued volume growth, with pricing constrained by payers |
| Initial generic entry |
A limited number of approved generics launch |
Rapid price pressure and gradual share loss |
| Mature generic market |
Multiple manufacturers compete on price and payer access |
Large net-price decline and branded volume erosion |
The size of the decline will depend on the number of approved suppliers, the timing of launches, settlement terms, authorized-generic strategy, payer substitution, and the survival of secondary patents. Chronic cardiovascular products generally experience substantial price erosion after multiple generic entrants, but prescriber persistence and complex fixed-dose combination manufacturing can slow the transition.
When does sacubitril and valsartan lose exclusivity?
Entresto does not have a single exclusivity date. Its protection is divided among regulatory exclusivity, Orange Book patents, pediatric exclusivity, settlement agreements, and country-specific rights.
What is the FDA regulatory status?
The FDA approved Entresto in 2015 for adults with heart failure with reduced ejection fraction. In 2019, the FDA approved a pediatric formulation and expanded the label to include children at least one year old with symptomatic heart failure and systemic left ventricular systolic dysfunction. In 2021, the agency expanded the adult indication to selected patients with heart failure with preserved ejection fraction (FDA, 2015, 2019, 2021).
The product is a small-molecule fixed-dose combination, not a biologic. Biosimilar competition is therefore not relevant. Competition will occur through the abbreviated new drug application pathway for generic versions.
What patents protect Entresto?
The principal U.S. patent protection has included patents covering the sacubitril/valsartan combination, pharmaceutical compositions, and therapeutic use. Public Orange Book records have identified multiple patents associated with Entresto, including:
| Patent |
General subject matter |
Listed expiration information |
| U.S. Patent No. 8,101,659 |
Sacubitril/valsartan pharmaceutical composition and related technology |
July 2026, including applicable patent-term adjustments or extensions shown in public listings |
| U.S. Patent No. 8,580,598 |
Combination and formulation-related protection |
Later expiration than the core composition patent |
| U.S. Patent No. 9,066,910 |
Additional formulation or use-related protection |
Later-term protection reported in public patent records |
The precise barrier to generic launch depends on which patents remain listed, whether a generic applicant certifies invalidity or non-infringement, whether litigation is filed within the statutory period, and whether a court grants an injunction. FDA Orange Book patent listings are controlling for regulatory certification mechanics but do not determine ultimate patent validity (FDA, 2024a).
What is the Orange Book status of Entresto?
Entresto is listed in the FDA Orange Book as a prescription drug with patents that can trigger Paragraph IV litigation. A generic applicant seeking approval before listed patent expiration may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed.
The first Paragraph IV filing can create a 180-day period of generic exclusivity under the Hatch-Waxman Act, subject to the statutory rules governing forfeiture and eligibility. Multiple applicants can also enter through settlements or later approvals if the first filer does not launch.
Which companies are challenging sacubitril and valsartan patents?
Generic-drug manufacturers have pursued U.S. approval or challenged Entresto patent protection. Public litigation and regulatory activity have involved companies such as:
- Teva Pharmaceuticals
- Mylan, now part of Viatris
- Dr. Reddy’s Laboratories
- Zydus Pharmaceuticals
- Lupin
- MSN Laboratories
- Torrent Pharmaceuticals
- Sun Pharmaceutical Industries
The competitive field can change as applications are withdrawn, settled, transferred, or approved. The existence of a Paragraph IV challenge does not establish that a generic will launch. Approval timing depends on FDA review, patent litigation, settlement restrictions, and commercial readiness.
What patent litigation affects Entresto?
Entresto has been the subject of patent disputes in the United States involving generic manufacturers. The disputes have generally concerned the scope, validity, and enforceability of patents covering the combination, dosage forms, and methods of treating heart failure.
How do settlement agreements affect generic launch?
Brand-generic settlements can establish a negotiated launch date before the latest patent expiration. A settlement may include:
- A licensed entry date.
- Restrictions on the formulation or dosage strength.
- An authorized-generic arrangement.
- Patent litigation dismissal.
- A covenant not to sue on specified patents.
- Terms governing pediatric or other formulations.
The economic significance of a settlement depends on whether it permits one or several generic manufacturers to launch, whether the launch date is at-risk or guaranteed, and whether the brand company supplies an authorized generic. A negotiated launch before full patent expiration can reduce litigation uncertainty while preserving a substantial portion of branded revenue.
What formulations are protected by sacubitril and valsartan patents?
Entresto is sold primarily as oral tablets in several strengths. The pediatric formulation is an oral suspension, marketed in the United States as an approved product for children who cannot use tablets.
Why is the pediatric formulation commercially relevant?
The pediatric formulation expands the addressable population and may create separate regulatory and patent considerations. It also introduces manufacturing and bioequivalence issues that are less significant for standard tablets. Generic applicants must demonstrate equivalence for the relevant dosage form and comply with FDA requirements for inactive ingredients, device or dosing components where applicable, and stability.
The pediatric indication has limited revenue impact compared with the adult market but can extend physician familiarity and strengthen lifecycle positioning.
How strong is the Entresto patent estate?
The patent estate is commercially meaningful but less durable than the product’s clinical franchise. Its strengths are:
- A differentiated combination of two active ingredients.
- Multiple dosage strengths.
- Formulation and composition claims.
- Method-of-use protection linked to heart-failure treatment.
- A large clinical evidence base supporting brand preference.
- Regulatory and market barriers in countries where patents remain enforceable.
Its weaknesses are:
- The product is a small-molecule combination eligible for conventional generic approval.
- The core clinical indication is well defined and relatively easy for generic applicants to target.
- Multiple manufacturers have financial incentives to enter.
- Method-of-use patents can be designed around through labeling strategies.
- The largest revenue concentration is in the United States and other markets where loss of exclusivity creates rapid payer pressure.
The estate is best characterized as moderate to strong before generic entry, with declining practical power once several manufacturers obtain approvals.
What generic entry risks exist for Entresto?
Generic entry risk is high because the product has substantial sales, chronic use, and a clear substitution opportunity. The principal variables are timing and intensity.
Generic launch scenarios
| Scenario |
Description |
Financial effect |
| One authorized or licensed generic |
Limited early competition |
Slower price decline; Novartis retains meaningful economics |
| Two to four independent generics |
Rapid payer substitution |
Significant net-price and share erosion |
| Broad multi-source entry |
Several manufacturers launch near the same date |
Steep price compression and faster branded decline |
| Delayed or restricted entry |
Litigation or settlement limits availability |
Extended branded revenue runway |
The combination product has manufacturing complexity above that of a single active ingredient, but the barrier is not comparable to a biologic or sterile injectable. Manufacturers with established oral-solid-dose capacity can generally compete once regulatory and patent barriers are resolved.
How does sacubitril and valsartan compare with competing heart-failure drugs?
| Product or class |
Competitive position |
Effect on Entresto |
| Enalapril and other ACE inhibitors |
Low-cost generic standards of care |
Create price pressure but are clinically less differentiated |
| Generic ARBs |
Low-cost alternatives |
Limit use in cost-sensitive markets |
| SGLT2 inhibitors |
Rapidly expanding heart-failure class |
Compete for treatment budgets but are often used with Entresto |
| Beta blockers |
Foundational adjunctive therapy |
Complement rather than directly replace Entresto |
| Mineralocorticoid receptor antagonists |
Adjunctive therapy |
Complementary |
| Vericiguat |
Narrower heart-failure positioning |
Limited direct substitution |
| Omecamtiv mecarbil and other investigational mechanisms |
Potential future competitors |
Could affect treatment sequencing if broadly adopted |
Entresto’s strongest competitive advantage is its clinical evidence in reduced ejection fraction and its integration into guideline-directed combination therapy. Its principal weakness is cost relative to generic ACE inhibitors and ARBs.
What licensing deals affect sacubitril and valsartan?
Novartis owns the global Entresto brand and has relied primarily on internal commercialization rather than a high-profile external licensing model for the core product. Regional commercialization, distribution, and manufacturing arrangements can still affect market access, but they are different from a co-development license that divides ownership of the active pharmaceutical technology.
The commercial structure gives Novartis control over pricing, supply, lifecycle management, and authorized-generic strategy. It also concentrates post-expiration exposure in a single company.
What is the geographic coverage of Entresto patents?
Patent and exclusivity risk varies significantly by market:
- United States: The most commercially important market, with Orange Book-listed patents and Paragraph IV exposure.
- European Union: Patent protection and supplementary protection certificates differ by country and can extend the effective term beyond the base patent.
- Japan: Regulatory and patent timing depends on local approval and patent linkage practices.
- China: Local patent validity, reimbursement negotiations, and volume-based procurement can affect net sales even before full generic entry.
- Emerging markets: Earlier generic competition is common, but branded price levels and market shares vary widely.
The global revenue curve will not follow the U.S. curve exactly. Some countries will experience patent expiry, tender pressure, or generic substitution earlier, while others will maintain branded sales through reimbursement and physician preference.
What is the FDA pathway for generic sacubitril and valsartan?
Generic applicants generally use an ANDA demonstrating bioequivalence to Entresto. They do not repeat the full clinical efficacy program required for the original approval. Applicants must address the relevant dosage strengths, active ingredients, product quality, labeling, and any listed patents.
A Paragraph IV certification can trigger litigation if the brand owner files within the statutory period. A first applicant may qualify for 180-day generic exclusivity, but the exclusivity period can be affected by forfeiture provisions, settlement terms, court outcomes, and other applicants’ regulatory status.
What revenue exposure does Novartis face?
Entresto is one of Novartis’s largest products. With 2023 sales of approximately $6.0 billion, it represented a material share of group revenue and an important contributor to the company’s growth profile (Novartis, 2024).
The exposure is substantial but manageable at the group level because Novartis has diversified franchises in oncology, immunology, neuroscience, and cardiovascular medicines. The more important investment issue is the rate of decline after generic entry and whether newer products replace Entresto’s contribution.
Potential offsets include:
- Continued international volume growth before expiry.
- Expansion in preserved-ejection-fraction populations.
- Price and access optimization.
- New indications supported by clinical evidence.
- Authorized-generic economics.
- Growth from newer Novartis medicines, including cardiometabolic and immunology products.
Key Takeaways
- Entresto sales increased from roughly $0.5 billion in 2017 to $6.0 billion in 2023.
- Growth has been driven by clinical evidence, guideline adoption, chronic use, and expansion into broader heart-failure populations.
- The product is a small-molecule combination, so biosimilar risk does not apply.
- U.S. generic risk is high because multiple manufacturers have challenged or pursued approval against Entresto-related patents.
- The Orange Book patent estate provides meaningful protection but does not eliminate post-expiration price erosion.
- Pediatric suspension and formulation patents provide lifecycle support but are unlikely to protect the entire adult revenue base.
- Novartis faces material revenue exposure, with the impact depending on the number and timing of generic launches.
- SGLT2 inhibitors are the most important emerging complementary class, while generic ACE inhibitors and ARBs remain the main price-based alternatives.
- Global loss of exclusivity will be staggered by country, patent term, settlement, reimbursement, and local generic competition.
FAQs
What is the active ingredient in Entresto?
Entresto contains sacubitril and valsartan. Sacubitril inhibits neprilysin after conversion to its active metabolite, while valsartan blocks the angiotensin II type 1 receptor.
Is sacubitril/valsartan a biologic drug?
No. It is an oral small-molecule fixed-dose combination. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.
Can generic manufacturers copy the Entresto pediatric suspension?
They may seek approval for an equivalent pediatric dosage form, but the regulatory requirements and patent position may differ from those applicable to adult tablets.
Will generic sacubitril/valsartan be automatically substituted?
Substitution depends on FDA approval, state pharmacy laws, payer formularies, product ratings, and whether the generic has an equivalent therapeutic rating. Commercial substitution may accelerate when multiple manufacturers are available.
What is the main investment risk for Entresto?
The main risk is accelerated U.S. generic entry followed by rapid price compression. The severity of the decline will depend on settlement dates, the number of entrants, authorized-generic strategy, and the ability of Novartis to replace Entresto revenue with newer products.
References
-
Food and Drug Administration. (2015). FDA approves new drug to treat heart failure. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2019). FDA approves new oral suspension formulation of Entresto for pediatric patients with heart failure. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2021). FDA expands indication for Entresto to include certain patients with heart failure with preserved ejection fraction. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fed dispari, G., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032.
-
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
-
Novartis. (2018-2024). Annual report and financial results. Novartis AG.
